董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul S. Herendeen | 男 | Independent Director | 69 | 未披露 | 未持股 | 2025-07-07 |
| Denise Scots Knight | 女 | Independent Director | 66 | 25.00万美元 | 未持股 | 2025-07-07 |
| Kapila K. Anand | 女 | Independent Director | 71 | 26.80万美元 | 未持股 | 2025-07-07 |
| Michael J. Harrington | 男 | Independent Director | 62 | 25.00万美元 | 未持股 | 2025-07-07 |
| Kirk P. McDonald | 男 | Independent Director | 58 | 25.00万美元 | 未持股 | 2025-07-07 |
| Stacey Ma | -- | Independent Director | -- | 未披露 | 未持股 | 2025-07-07 |
| R. David Hoover | 男 | Independent Director | 80 | 36.60万美元 | 未持股 | 2025-07-07 |
| Lawrence E. Kurzius | 男 | Chairman of the Board | 66 | 26.60万美元 | 未持股 | 2025-07-07 |
| Art A. Garcia | 男 | Independent Director | 63 | 25.00万美元 | 未持股 | 2025-07-07 |
| Deborah T. Kochevar | 女 | Independent Director | 68 | 25.00万美元 | 未持股 | 2025-07-07 |
| Jeffrey N. Simmons | 男 | President, Chief Executive Officer and Director | 58 | 895.88万美元 | 未持股 | 2025-07-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ramiro M. Cabral | 男 | Executive Vice President and President of Elanco International | 54 | 未披露 | 未持股 | 2025-07-07 |
| David S. Kinard | 男 | Executive Vice President, Human Resources, Corporate Communications and Administration | 58 | 286.08万美元 | 未持股 | 2025-07-07 |
| James M. Meer | 男 | Senior Vice President and Chief Accounting Officer | 55 | 未披露 | 未持股 | 2025-07-07 |
| Robert M. VanHimbergen | -- | Executive Vice President and Chief Financial Officer | -- | 未披露 | 未持股 | 2025-07-07 |
| Shiv O'Neill | -- | Executive Vice President, General Counsel and Corporate Secretary | -- | 未披露 | 未持股 | 2025-07-07 |
| Grace McArdle | -- | Executive Vice President, Manufacturing and Quality | -- | 未披露 | 未持股 | 2025-07-07 |
| Ellen de Brabander | -- | Executive Vice President, Innovation and Regulatory Affairs | -- | 未披露 | 未持股 | 2025-07-07 |
| Timothy J. Bettington | -- | Executive Vice President, Corporate Strategy and Market Development | -- | 未披露 | 未持股 | 2025-07-07 |
| Rajeev A. Modi | -- | Executive Vice President, U.S. Pet Health and Global Digital Transformation | -- | 未披露 | 未持股 | 2025-07-07 |
| Jose Manuel Correia de Simas | -- | Executive Vice President, U.S. Farm Animal Business | -- | 未披露 | 未持股 | 2025-07-07 |
| Jeffrey N. Simmons | 男 | President, Chief Executive Officer and Director | 58 | 895.88万美元 | 未持股 | 2025-07-07 |
董事简历
中英对照 | 中文 | 英文- Paul S. Herendeen
-
Paul S. Herendeen，自2016年8月起担任执行副总裁兼首席财务官。自2021年6月1日起，Herendeen先生将辞去首席财务官的职务，并将被任命为新设立的董事长兼首席执行官顾问。在加入Bausch Health之前，2014年至2016年8月，他担任Zoetis Inc.（动物健康和制药公司）的执行副总裁兼首席财务官。从2005年到2013年，从1998年到2001年，他担任专业制药公司Warner Chilcott的首席财务官。2001年至2005年，他在MedPointe Pharmaceuticals（一家私营医疗保健公司）担任执行副总裁兼首席财务官四年后，重新加入Warner Chilcott。在此之前，他在Dominion Income Management和Cornerstone Partners担任了9年的主要投资者，在那里他从事公司及其投资组合公司的投资以及并购。他在银行和公共会计领域度过了职业生涯的早期，曾在Oppenheimer & Company的投资银行集团、Continental Bank Corporation的资本市场集团担任过各种职务，并担任Arthur Andersen & Company的高级审计师。Herendeen先生自2020年12月以来一直担任Elanco Animal Health Inc.（一家上市的动物保健公司）的董事。他持有Virginia大学Darden School of Business的工商管理硕士学位和Boston College的工商管理学士学位。
Paul S. Herendeen has been Executive Vice President and Chief Financial Officer since August 2016. Effective June 1 2021 Mr. Herendeen will step down from his role as Chief Financial Officer, and will be appointed to the newly created role of Advisor to the Chairman and CEO. Prior to joining Bausch Health, he served as Executive Vice President and CFO of Zoetis Inc., an animal health and pharmaceuticals company, from 2014 to August 2016. From 2005 to 2013 and from 1998 to 2001 Mr. Herendeen served as CFO at Warner Chilcott, a specialty pharmaceuticals company. He rejoined Warner Chilcott after four years as EVP and CFO of MedPointe Pharmaceuticals, a privately held healthcare company, where he served as CFO from 2001 until 2005. Prior to that, Mr. Herendeen spent nine years as a principal investor at both Dominion Income Management and Cornerstone Partners, where he worked on investments as well as mergers and acquisitions for the firms and their portfolio companies. He spent the early part of his career in banking and public accounting, having held various positions with the investment banking group of Oppenheimer & Company, the capital markets group of Continental Bank Corporation and as a senior auditor with Arthur Andersen & Company. Mr. Herendeen has been a director of Elanco Animal Health Inc., a publicly traded animal health company, since December 2020. Mr. Herendeen earned a Master of Business Administration from the University of Virginia's Darden School of Business and holds a bachelor's degree in Business Administration from Boston College. - Paul S. Herendeen，自2016年8月起担任执行副总裁兼首席财务官。自2021年6月1日起，Herendeen先生将辞去首席财务官的职务，并将被任命为新设立的董事长兼首席执行官顾问。在加入Bausch Health之前，2014年至2016年8月，他担任Zoetis Inc.（动物健康和制药公司）的执行副总裁兼首席财务官。从2005年到2013年，从1998年到2001年，他担任专业制药公司Warner Chilcott的首席财务官。2001年至2005年，他在MedPointe Pharmaceuticals（一家私营医疗保健公司）担任执行副总裁兼首席财务官四年后，重新加入Warner Chilcott。在此之前，他在Dominion Income Management和Cornerstone Partners担任了9年的主要投资者，在那里他从事公司及其投资组合公司的投资以及并购。他在银行和公共会计领域度过了职业生涯的早期，曾在Oppenheimer & Company的投资银行集团、Continental Bank Corporation的资本市场集团担任过各种职务，并担任Arthur Andersen & Company的高级审计师。Herendeen先生自2020年12月以来一直担任Elanco Animal Health Inc.（一家上市的动物保健公司）的董事。他持有Virginia大学Darden School of Business的工商管理硕士学位和Boston College的工商管理学士学位。
- Paul S. Herendeen has been Executive Vice President and Chief Financial Officer since August 2016. Effective June 1 2021 Mr. Herendeen will step down from his role as Chief Financial Officer, and will be appointed to the newly created role of Advisor to the Chairman and CEO. Prior to joining Bausch Health, he served as Executive Vice President and CFO of Zoetis Inc., an animal health and pharmaceuticals company, from 2014 to August 2016. From 2005 to 2013 and from 1998 to 2001 Mr. Herendeen served as CFO at Warner Chilcott, a specialty pharmaceuticals company. He rejoined Warner Chilcott after four years as EVP and CFO of MedPointe Pharmaceuticals, a privately held healthcare company, where he served as CFO from 2001 until 2005. Prior to that, Mr. Herendeen spent nine years as a principal investor at both Dominion Income Management and Cornerstone Partners, where he worked on investments as well as mergers and acquisitions for the firms and their portfolio companies. He spent the early part of his career in banking and public accounting, having held various positions with the investment banking group of Oppenheimer & Company, the capital markets group of Continental Bank Corporation and as a senior auditor with Arthur Andersen & Company. Mr. Herendeen has been a director of Elanco Animal Health Inc., a publicly traded animal health company, since December 2020. Mr. Herendeen earned a Master of Business Administration from the University of Virginia's Darden School of Business and holds a bachelor's degree in Business Administration from Boston College.
- Denise Scots Knight
-
Denise Scots Knight，是Mereo BioPharma Group plc（一家专业生物制药公司）的共同创始人，也是其首席执行官和董事会成员，她自2015年以来一直担任该职位。Scots-Knight博士在生物制药行业拥有超过25年的经验，从事研发管理工作，并担任风险投资家。从2010年到2015年，Scots-Knight博士是全球生命科学风险投资公司Phase4 Partners Ltd.的管理合伙人。2004年至2010年，Scots-Knight博士担任野村Phase4 Ventures的负责人，该公司是日本领先金融机构野村国际集团（Nomura International plc）的风险投资附属公司。Scots-Knight博士曾在Oncomed Pharmaceuticals, Inc.、β胞核嘧啶制药、Nabriva Therapeutics AG和AlbireO的董事会任职。此外，Scots-Knight博士还被Labiotech UG评为欧洲生物技术领域15位领先的女性之一。
Denise Scots Knight, co-founded and is the Chief Executive Officer and member of the board of Mereo BioPharma Group plc, a specialty biopharmaceutical Company, positions she has held since 2015. Dr. Scots-Knight has more than 25 years of experience in the biopharmaceutical industry, working in research and development management and as a venture capitalist. From 2010 until 2015 Dr. Scots-Knight was the Managing Partner of Phase4 Partners Ltd., a global life science venture capital firm. From 2004 to 2010 Dr. Scots-Knight was head of Nomura Phase4 Ventures, a venture capital affiliate of Nomura International plc, a leading Japanese financial institution. Dr. Scots-Knight has served on the boards of directors of Oncomed Pharmaceuticals, Inc., Idenix Pharmaceuticals, Inc., Nabriva Therapeutics AG, and AlbireO. Additionally, Dr. Scots-Knight has been named one of the 15 leading women in European biotech by Labiotech UG. - Denise Scots Knight，是Mereo BioPharma Group plc（一家专业生物制药公司）的共同创始人，也是其首席执行官和董事会成员，她自2015年以来一直担任该职位。Scots-Knight博士在生物制药行业拥有超过25年的经验，从事研发管理工作，并担任风险投资家。从2010年到2015年，Scots-Knight博士是全球生命科学风险投资公司Phase4 Partners Ltd.的管理合伙人。2004年至2010年，Scots-Knight博士担任野村Phase4 Ventures的负责人，该公司是日本领先金融机构野村国际集团（Nomura International plc）的风险投资附属公司。Scots-Knight博士曾在Oncomed Pharmaceuticals, Inc.、β胞核嘧啶制药、Nabriva Therapeutics AG和AlbireO的董事会任职。此外，Scots-Knight博士还被Labiotech UG评为欧洲生物技术领域15位领先的女性之一。
- Denise Scots Knight, co-founded and is the Chief Executive Officer and member of the board of Mereo BioPharma Group plc, a specialty biopharmaceutical Company, positions she has held since 2015. Dr. Scots-Knight has more than 25 years of experience in the biopharmaceutical industry, working in research and development management and as a venture capitalist. From 2010 until 2015 Dr. Scots-Knight was the Managing Partner of Phase4 Partners Ltd., a global life science venture capital firm. From 2004 to 2010 Dr. Scots-Knight was head of Nomura Phase4 Ventures, a venture capital affiliate of Nomura International plc, a leading Japanese financial institution. Dr. Scots-Knight has served on the boards of directors of Oncomed Pharmaceuticals, Inc., Idenix Pharmaceuticals, Inc., Nabriva Therapeutics AG, and AlbireO. Additionally, Dr. Scots-Knight has been named one of the 15 leading women in European biotech by Labiotech UG.
- Kapila K. Anand
-
Kapila K. Anand，注册会计师，从1989年到2016年退休，她曾担任毕马威会计师事务所（KPMG LLP）的审计合伙人，后来成为咨询合伙人。她举行了各种各样的领导角色毕马威（KPMG）在她的任期内，包括担任审计签署合作伙伴通过萨班斯奥克斯利法案立法的发展，一个顾问合作伙伴构建和集成新的业务，和一个审计委员会联络伙伴和毕马威作为董事会成员为美国和美洲。在她的职业生涯中，她曾担任毕马威的全国合伙人，并担任毕马威首任公共政策战略的设计师，负责协调美国事务所对影响该事务所各行业客户的公共政策变化的回应。此外，她还建立了公司的旅游、休闲和酒店业务，并担任其全国部门负责人。她目前担任Extended Stay America, Inc.和Omega Healthcare Investors, Inc.的董事会成员。
Kapila K. Anand, CPA, served as an audit partner and later an advisory partner at KPMG LLP, an accounting firm, from 1989 until her retirement in 2016. She held a variety of leadership roles during her tenure at KPMG, including serving as an audit signing partner through the evolution of Sarbanes Oxley legislation, an advisory partner building and integrating new businesses, and an audit committee liaison partner and as a KPMG LLP Board member for the U.S. and Americas. During her career, she served as KPMG's national partner-in-charge, and architect of KPMG's inaugural public policy strategy responsible for coordinating the U.S. firm's response to public policy changes that impacted the firm's clients across industries. Additionally, she established the firm's travel, leisure and hospitality practice and served as its national segment leader. Ms. Anand currently serves as a member of the board of directors of Extended Stay America, Inc. and Omega Healthcare Investors, Inc. - Kapila K. Anand，注册会计师，从1989年到2016年退休，她曾担任毕马威会计师事务所（KPMG LLP）的审计合伙人，后来成为咨询合伙人。她举行了各种各样的领导角色毕马威（KPMG）在她的任期内，包括担任审计签署合作伙伴通过萨班斯奥克斯利法案立法的发展，一个顾问合作伙伴构建和集成新的业务，和一个审计委员会联络伙伴和毕马威作为董事会成员为美国和美洲。在她的职业生涯中，她曾担任毕马威的全国合伙人，并担任毕马威首任公共政策战略的设计师，负责协调美国事务所对影响该事务所各行业客户的公共政策变化的回应。此外，她还建立了公司的旅游、休闲和酒店业务，并担任其全国部门负责人。她目前担任Extended Stay America, Inc.和Omega Healthcare Investors, Inc.的董事会成员。
- Kapila K. Anand, CPA, served as an audit partner and later an advisory partner at KPMG LLP, an accounting firm, from 1989 until her retirement in 2016. She held a variety of leadership roles during her tenure at KPMG, including serving as an audit signing partner through the evolution of Sarbanes Oxley legislation, an advisory partner building and integrating new businesses, and an audit committee liaison partner and as a KPMG LLP Board member for the U.S. and Americas. During her career, she served as KPMG's national partner-in-charge, and architect of KPMG's inaugural public policy strategy responsible for coordinating the U.S. firm's response to public policy changes that impacted the firm's clients across industries. Additionally, she established the firm's travel, leisure and hospitality practice and served as its national segment leader. Ms. Anand currently serves as a member of the board of directors of Extended Stay America, Inc. and Omega Healthcare Investors, Inc.
- Michael J. Harrington
-
Michael J. Harrington，他一直担任Elanco Animal Health Incorporated董事会成员（2018年9月以来）。他曾担任礼来公司的各种法律职务，包括高级副总裁兼总法律顾问（从2013年到2020年1月退休）、全球制药运营副总裁兼副总法律顾问（从2010年到2012年）、公司副总裁兼总法律顾问（从2004年到2010年）。
Michael J. Harrington served in various legal roles for Eli Lilly & Company, including Senior Vice President and General Counsel from 2013 until his retirement in January 2020 Vice President and Deputy General Counsel of Global Pharmaceutical Operations from 2010 to 2012 and Vice President and General Counsel, Corporate from 2004 to 2010. - Michael J. Harrington，他一直担任Elanco Animal Health Incorporated董事会成员（2018年9月以来）。他曾担任礼来公司的各种法律职务，包括高级副总裁兼总法律顾问（从2013年到2020年1月退休）、全球制药运营副总裁兼副总法律顾问（从2010年到2012年）、公司副总裁兼总法律顾问（从2004年到2010年）。
- Michael J. Harrington served in various legal roles for Eli Lilly & Company, including Senior Vice President and General Counsel from 2013 until his retirement in January 2020 Vice President and Deputy General Counsel of Global Pharmaceutical Operations from 2010 to 2012 and Vice President and General Counsel, Corporate from 2004 to 2010.
- Kirk P. McDonald
-
Kirk P. McDonald自2019年3月起担任董事会成员。McDonald先生自2019年9月起担任AT&T的广告公司Xandr的首席商务官，自2017年起担任Xandr的首席营销官。加入Xandr之前，从2011年到2017年，McDonald先生担任PubMatic的总裁，这是一家开发和实施在线广告软件和战略的公司。在加入PubMatic之前，他曾担任Time Inc.的数字总裁（2009年至2011年），以及Fortune|Money Group的首席广告官。他还曾担任DRIVEpm和Atlas的销售、营销和客户服务高级副总裁，这两家公司都是微软的广告业务部门，并在CNET、Ziff Davis和Conde Nast担任各种职务。McDonald是几家专业和非盈利董事会的成员。他曾是卢马合作伙伴董事会的顾问，目前是非营利组织Code Interactive的主席，该组织专注于激励来自服务不足社区的下一代技术领袖。
Kirk P. McDonald is the Chief Executive Officer of GroupM North America, a media investment company, a position he has held since August 2020. Previously, Mr. McDonald served as the Chief Business Officer of Xandr, AT&T's advertising company from September 2019 to August 2020 and from November 2017 to September 2019 he served as Xandr's Chief Marketing Officer. Prior to Xandr, from 2011 to 2017 Mr. McDonald served as the President of PubMatic, a company developing and implementing online advertising software and strategies. Before joining PubMatic, he was President of Digital at Time Inc., from 2009 to 2011 and the Chief Advertising Officer of the Fortune|Money Group. He has also served as the SVP of Sales, Marketing and Client Services for DRIVEpm and Atlas, both units of Microsoft's advertising business, as well as in various roles at CNET, Ziff Davis and Condé Nast. Mr. McDonald serves on several professional and not-for-profit boards. He was a former advisor on the LUMA Partners board and is currently the Co-Chairman of MOUSE, a non-profit focused on inspiring the next generation of technology leaders from underserved communities. - Kirk P. McDonald自2019年3月起担任董事会成员。McDonald先生自2019年9月起担任AT&T的广告公司Xandr的首席商务官，自2017年起担任Xandr的首席营销官。加入Xandr之前，从2011年到2017年，McDonald先生担任PubMatic的总裁，这是一家开发和实施在线广告软件和战略的公司。在加入PubMatic之前，他曾担任Time Inc.的数字总裁（2009年至2011年），以及Fortune|Money Group的首席广告官。他还曾担任DRIVEpm和Atlas的销售、营销和客户服务高级副总裁，这两家公司都是微软的广告业务部门，并在CNET、Ziff Davis和Conde Nast担任各种职务。McDonald是几家专业和非盈利董事会的成员。他曾是卢马合作伙伴董事会的顾问，目前是非营利组织Code Interactive的主席，该组织专注于激励来自服务不足社区的下一代技术领袖。
- Kirk P. McDonald is the Chief Executive Officer of GroupM North America, a media investment company, a position he has held since August 2020. Previously, Mr. McDonald served as the Chief Business Officer of Xandr, AT&T's advertising company from September 2019 to August 2020 and from November 2017 to September 2019 he served as Xandr's Chief Marketing Officer. Prior to Xandr, from 2011 to 2017 Mr. McDonald served as the President of PubMatic, a company developing and implementing online advertising software and strategies. Before joining PubMatic, he was President of Digital at Time Inc., from 2009 to 2011 and the Chief Advertising Officer of the Fortune|Money Group. He has also served as the SVP of Sales, Marketing and Client Services for DRIVEpm and Atlas, both units of Microsoft's advertising business, as well as in various roles at CNET, Ziff Davis and Condé Nast. Mr. McDonald serves on several professional and not-for-profit boards. He was a former advisor on the LUMA Partners board and is currently the Co-Chairman of MOUSE, a non-profit focused on inspiring the next generation of technology leaders from underserved communities.
- Stacey Ma
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- R. David Hoover
-
R. David Hoover，从2002年至2013年担任波尔公司董事长；这是一家为商业客户和政府客户提供产品及技术服务的公司。2001年 至2010年，他曾任该公司的总裁兼CEO；2000年 至2001年，担任首席营运官；1998年至2000年，担任财务总监。此外，胡佛先生还是多个组织机构的成员：迪堡大学理事会、印第安纳大学凯利商学院院长委员会。他还任职于多个公司的董事会：上市公司有波尔公司、劲量控股公司、Steelcase公司；非营利性公司有波尔得社区医院、科罗拉多州儿童医院；还任职于早前公司的公共董事会：厄文金融公司、奎斯特国际公司。
R. David Hoover has served as the Chairman of the Board since May 2018. Mr. Hoover has been retired since 2013. Prior to that Mr. Hoover served in various roles at Ball Corporation, a company supplying innovative, sustainable packaging solutions, aerospace operations, and other technologies and services, including as Chairman from 2002 to 2013 Chief Executive Officer from 2010 to 2011 President and Chief Executive Officer from 2001 to 2010 Chief Operating Officer from 2000 to 2001 and Chief Financial Officer from 1998 to 2000. Mr. Hoover currently serves on the board of directors of Children's Hospital Colorado and has previously served on the board of directors of Ball Corporation, Edgewell Personal Care Company, and Eli Lilly & Company. - R. David Hoover，从2002年至2013年担任波尔公司董事长；这是一家为商业客户和政府客户提供产品及技术服务的公司。2001年 至2010年，他曾任该公司的总裁兼CEO；2000年 至2001年，担任首席营运官；1998年至2000年，担任财务总监。此外，胡佛先生还是多个组织机构的成员：迪堡大学理事会、印第安纳大学凯利商学院院长委员会。他还任职于多个公司的董事会：上市公司有波尔公司、劲量控股公司、Steelcase公司；非营利性公司有波尔得社区医院、科罗拉多州儿童医院；还任职于早前公司的公共董事会：厄文金融公司、奎斯特国际公司。
- R. David Hoover has served as the Chairman of the Board since May 2018. Mr. Hoover has been retired since 2013. Prior to that Mr. Hoover served in various roles at Ball Corporation, a company supplying innovative, sustainable packaging solutions, aerospace operations, and other technologies and services, including as Chairman from 2002 to 2013 Chief Executive Officer from 2010 to 2011 President and Chief Executive Officer from 2001 to 2010 Chief Operating Officer from 2000 to 2001 and Chief Financial Officer from 1998 to 2000. Mr. Hoover currently serves on the board of directors of Children's Hospital Colorado and has previously served on the board of directors of Ball Corporation, Edgewell Personal Care Company, and Eli Lilly & Company.
- Lawrence E. Kurzius
-
Lawrence E. Kurzius是Global Consumer Business公司的总裁兼首席行政官（2013年至今），也是 McCormick International 公司的总裁（2008年至2013年）。
Lawrence E. Kurzius,served as the Chief Executive Officer of McCormick & Company, Incorporated (NYSE: MKC) from 2016 to 2023 and as its President from 2015 to 2022. Mr. Kurzius currently serves as a director of McCormick and previously served as its Executive Chairman from 2023-2024, and as its Chairman from 2017 to 2023. Mr. Kurzius held roles of increasing responsibility at McCormick beginning in 2003, including President and Chief Operating Officer (2015-2016), President of McCormick's global consumer business (2013-2016), Chief Administrative Officer (2013-2015), President of the international business (2008-2013), and President of EMEA (2007-2008). Previously, Mr. Kurzius was the Chief Executive Officer of Zatarain's, where he worked for 12 years before the company was acquired by McCormick. Prior to this, Mr. Kurzius was a marketing executive with the Quaker Oats Company and Mars Inc.'s Uncle Ben's Company. Mr. Kurzius graduated from Princeton University magna cum laude with a degree in economics. - Lawrence E. Kurzius是Global Consumer Business公司的总裁兼首席行政官（2013年至今），也是 McCormick International 公司的总裁（2008年至2013年）。
- Lawrence E. Kurzius,served as the Chief Executive Officer of McCormick & Company, Incorporated (NYSE: MKC) from 2016 to 2023 and as its President from 2015 to 2022. Mr. Kurzius currently serves as a director of McCormick and previously served as its Executive Chairman from 2023-2024, and as its Chairman from 2017 to 2023. Mr. Kurzius held roles of increasing responsibility at McCormick beginning in 2003, including President and Chief Operating Officer (2015-2016), President of McCormick's global consumer business (2013-2016), Chief Administrative Officer (2013-2015), President of the international business (2008-2013), and President of EMEA (2007-2008). Previously, Mr. Kurzius was the Chief Executive Officer of Zatarain's, where he worked for 12 years before the company was acquired by McCormick. Prior to this, Mr. Kurzius was a marketing executive with the Quaker Oats Company and Mars Inc.'s Uncle Ben's Company. Mr. Kurzius graduated from Princeton University magna cum laude with a degree in economics.
- Art A. Garcia
-
Art A. Garcia，莱德系统公司（“莱德”）的退休首席财务官，该公司是一家车队管理、供应链管理和物流解决方案提供商（2010-2019年）。莱德高级副总裁兼财务总监（2005-2009年）。Garcia先生是一名注册会计师，在加入Ryder.MR之前，他的职业生涯始于Coopers & LYBrand。在Ryder任职期间，Garcia先生负责包括集团董事会计服务，以及高级副总裁和公司财务总监，在他被任命为首席财务官之前。
Art A. Garcia,retired in 2019 as the executive vice president and chief financial officer of Ryder System, Inc. (NYSE: R), a commercial fleet and supply chain management solutions company ("Ryder"), a position he had held since 2010. Previously, Mr. Garcia served as senior vice president, controller and chief accounting officer of Ryder from 2005 to 2010. Mr. Garcia joined Ryder in 1997 as senior manager of corporate accounting. He later served as director of corporate accounting and, subsequently, as group director of accounting services. Prior to joining Ryder, Mr. Garcia spent 14 years with the Miami office of the accounting firm Coopers & Lybrand LLP as senior manager of business assurance. Mr. Garcia has served on the board of Elanco Animal Health (NYSE: ELAN), a provider of products and services to improve animal health production in more than 90 countries around the world since 2019, and serves as a member of the Audit Committee and the Finance and Oversight Committee; American Electric Power (NASDAQ: AEP), an electric public utility company, delivering electricity and custom energy solutions, since 2019, where he serves as chair of the Audit Committee and a member of the Director & Corporate Governance, Finance, and Policy Committees; and Raymond James Financial, Inc. (NYSE: RJF), a leading diversified financial services company providing private client group, capital markets, asset management, banking and other services to individuals, corporation and municipalities, since 2023, where he serves as a member of the Risk Committee. - Art A. Garcia，莱德系统公司（“莱德”）的退休首席财务官，该公司是一家车队管理、供应链管理和物流解决方案提供商（2010-2019年）。莱德高级副总裁兼财务总监（2005-2009年）。Garcia先生是一名注册会计师，在加入Ryder.MR之前，他的职业生涯始于Coopers & LYBrand。在Ryder任职期间，Garcia先生负责包括集团董事会计服务，以及高级副总裁和公司财务总监，在他被任命为首席财务官之前。
- Art A. Garcia,retired in 2019 as the executive vice president and chief financial officer of Ryder System, Inc. (NYSE: R), a commercial fleet and supply chain management solutions company ("Ryder"), a position he had held since 2010. Previously, Mr. Garcia served as senior vice president, controller and chief accounting officer of Ryder from 2005 to 2010. Mr. Garcia joined Ryder in 1997 as senior manager of corporate accounting. He later served as director of corporate accounting and, subsequently, as group director of accounting services. Prior to joining Ryder, Mr. Garcia spent 14 years with the Miami office of the accounting firm Coopers & Lybrand LLP as senior manager of business assurance. Mr. Garcia has served on the board of Elanco Animal Health (NYSE: ELAN), a provider of products and services to improve animal health production in more than 90 countries around the world since 2019, and serves as a member of the Audit Committee and the Finance and Oversight Committee; American Electric Power (NASDAQ: AEP), an electric public utility company, delivering electricity and custom energy solutions, since 2019, where he serves as chair of the Audit Committee and a member of the Director & Corporate Governance, Finance, and Policy Committees; and Raymond James Financial, Inc. (NYSE: RJF), a leading diversified financial services company providing private client group, capital markets, asset management, banking and other services to individuals, corporation and municipalities, since 2023, where he serves as a member of the Risk Committee.
- Deborah T. Kochevar
-
Deborah T. Kochevar，弗莱彻法律与外交学院高级研究员，专注于Global One健康与健康外交，自2019年起担任塔夫茨大学卡明斯兽医学院名誉院长。从2018年到2019年，Kochevar博士担任教务长和临时高级副总裁，从2006年到2018年，担任塔夫茨大学卡明斯兽医学院院长。此前，Kochevar博士是德克萨斯农工大学兽医和生物医学科学学院的长期教员和行政人员，在那里她担任兽医医学教育的Wiley教席。Kochevar博士是美国兽医学院协会和美国兽医临床药理学学院的前任主席。Kochevar博士活跃于美国兽医医学协会，曾担任其教育委员会和外国兽医毕业生教育委员会主席。Kochevar博士担任Elanco Inc.的董事。Kochevar博士自2008年10月起担任董事。Kochevar博士入选董事会是为了表彰她作为生命科学领域非常杰出的学者和教育家的独特视角。作为美国兽医临床药理学学院的一名寄宿外交官，拥有细胞和分子生物学博士学位并结合D.V.M。学位，并拥有比较和转化医学以及复杂动物模型的深厚知识基础，Kochevar博士的培训和经验特别适合于了解和提供对兽医医学、合同研究和药物开发支持活动的见解。Kochevar博士还通过持续参与生物医学专业和贸易组织以及Global OneHealth，为董事会提供当前的行业和科学见解。
Deborah T. Kochevar,is Senior Fellow, The Fletcher School of Law and Diplomacy, with a focus on Global One Health and health diplomacy, and Dean Emerita of Cummings School of Veterinary Medicine at Tufts University since 2019. From 2018 until 2019, Dr. Kochevar served as Provost and Senior Vice President ad interim and, from 2006 until 2018, as Dean of Cummings School of Veterinary Medicine at Tufts University. Previously, Dr. Kochevar was a long-time faculty member and administrator at the College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, where she held the Wiley Chair of Veterinary Medical Education. Dr. Kochevar is a past president of the Association of American Veterinary Medical Colleges and American College of Veterinary Clinical Pharmacology. Dr. Kochevar is active in the American Veterinary Medical Association, having chaired its Council on Education and the Educational Commission for Foreign Veterinary Graduates. Dr. Kochevar serves as a director at Elanco Inc. Dr. Kochevar has been a director since October 2008. - Deborah T. Kochevar，弗莱彻法律与外交学院高级研究员，专注于Global One健康与健康外交，自2019年起担任塔夫茨大学卡明斯兽医学院名誉院长。从2018年到2019年，Kochevar博士担任教务长和临时高级副总裁，从2006年到2018年，担任塔夫茨大学卡明斯兽医学院院长。此前，Kochevar博士是德克萨斯农工大学兽医和生物医学科学学院的长期教员和行政人员，在那里她担任兽医医学教育的Wiley教席。Kochevar博士是美国兽医学院协会和美国兽医临床药理学学院的前任主席。Kochevar博士活跃于美国兽医医学协会，曾担任其教育委员会和外国兽医毕业生教育委员会主席。Kochevar博士担任Elanco Inc.的董事。Kochevar博士自2008年10月起担任董事。Kochevar博士入选董事会是为了表彰她作为生命科学领域非常杰出的学者和教育家的独特视角。作为美国兽医临床药理学学院的一名寄宿外交官，拥有细胞和分子生物学博士学位并结合D.V.M。学位，并拥有比较和转化医学以及复杂动物模型的深厚知识基础，Kochevar博士的培训和经验特别适合于了解和提供对兽医医学、合同研究和药物开发支持活动的见解。Kochevar博士还通过持续参与生物医学专业和贸易组织以及Global OneHealth，为董事会提供当前的行业和科学见解。
- Deborah T. Kochevar,is Senior Fellow, The Fletcher School of Law and Diplomacy, with a focus on Global One Health and health diplomacy, and Dean Emerita of Cummings School of Veterinary Medicine at Tufts University since 2019. From 2018 until 2019, Dr. Kochevar served as Provost and Senior Vice President ad interim and, from 2006 until 2018, as Dean of Cummings School of Veterinary Medicine at Tufts University. Previously, Dr. Kochevar was a long-time faculty member and administrator at the College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, where she held the Wiley Chair of Veterinary Medical Education. Dr. Kochevar is a past president of the Association of American Veterinary Medical Colleges and American College of Veterinary Clinical Pharmacology. Dr. Kochevar is active in the American Veterinary Medical Association, having chaired its Council on Education and the Educational Commission for Foreign Veterinary Graduates. Dr. Kochevar serves as a director at Elanco Inc. Dr. Kochevar has been a director since October 2008.
- Jeffrey N. Simmons
-
Jeffrey N. Simmonsis Elanco，自2018年7月起担任总裁兼首席执行官。从2008年到2018年9月，Simmons担任礼来公司（Eli Lilly& company’Lilly）的Elanco Animal Health Incorporated总裁和礼来公司的高级副总裁，当时他带领公司从礼来公司分离出来，最终Elanco在纽约证券交易所上市，成为一家专门致力于动物保健的独立上市公司。2008年之前，simmons先生在Elanco担任多个领导职务，包括地区销售经理、国际营销经理、巴西国家总监、西欧地区总监、美国和全球研发执行董事。在他任职期间，Elanco的规模显著扩大，完成了几次收购，成为第一家推出ESG承诺的独立动物保健公司，并建立了五项新业务，包括10亿美元的宠物保健业务和领先的水产养殖业务。最近，他策划了该行业迄今为止最大的收购，完成了Elanco对拜耳动物保健业务的收购。simmons先生还担任过许多领导职务，包括担任Chiquita brands的前董事会成员和薪酬委员会主席。Simmons已经完成了动物健康主席，FFA基金会董事会主席，以及印第安纳州Gleaners Food Bank董事会成员的任期。
Jeffrey N. Simmonsis Elanco's President and Chief Executive Officer,a position he has held since July 2018.Mr.Simmons served as the President of the Elanco Animal Health division of Eli Lilly&Company 'Lilly'and Senior Vice President of Lilly from 2008 until September 2018 when he navigated the company's separation from Lilly, culminating with Elanco's listing on the New York Stock Exchange as an independent public company solely dedicated to animal health.Prior to 2008 Mr.Simmons held various leadership roles for Elanco,including District Sales Manager,International Marketing Manager,Country Director for Brazil,Area Director for Western Europe and Executive Director for U.S.and Global Research&Development.During Mr.Simmons'tenure, Elanco has significantly increased in size,completed several acquisitions,and become the first independent animal health company to launch ESG commitments and built five new businesses,including a $1 billion pet health business,and a leading aquaculture business.Most recently,he has orchestrated the industry's largest acquisition to date with the completion of Elanco's purchase of Bayer's animal health business.Mr.Simmons has also held a number of leadership positions,including serving as a former board member and Chairman of the Compensation Committee for Chiquita Brands.Mr. Simmons has completed terms as President of the Health for Animals, Chairman of the FFA Foundation Board,and as a board member of Gleaners Food Bank of Indiana. - Jeffrey N. Simmonsis Elanco，自2018年7月起担任总裁兼首席执行官。从2008年到2018年9月，Simmons担任礼来公司（Eli Lilly& company’Lilly）的Elanco Animal Health Incorporated总裁和礼来公司的高级副总裁，当时他带领公司从礼来公司分离出来，最终Elanco在纽约证券交易所上市，成为一家专门致力于动物保健的独立上市公司。2008年之前，simmons先生在Elanco担任多个领导职务，包括地区销售经理、国际营销经理、巴西国家总监、西欧地区总监、美国和全球研发执行董事。在他任职期间，Elanco的规模显著扩大，完成了几次收购，成为第一家推出ESG承诺的独立动物保健公司，并建立了五项新业务，包括10亿美元的宠物保健业务和领先的水产养殖业务。最近，他策划了该行业迄今为止最大的收购，完成了Elanco对拜耳动物保健业务的收购。simmons先生还担任过许多领导职务，包括担任Chiquita brands的前董事会成员和薪酬委员会主席。Simmons已经完成了动物健康主席，FFA基金会董事会主席，以及印第安纳州Gleaners Food Bank董事会成员的任期。
- Jeffrey N. Simmonsis Elanco's President and Chief Executive Officer,a position he has held since July 2018.Mr.Simmons served as the President of the Elanco Animal Health division of Eli Lilly&Company 'Lilly'and Senior Vice President of Lilly from 2008 until September 2018 when he navigated the company's separation from Lilly, culminating with Elanco's listing on the New York Stock Exchange as an independent public company solely dedicated to animal health.Prior to 2008 Mr.Simmons held various leadership roles for Elanco,including District Sales Manager,International Marketing Manager,Country Director for Brazil,Area Director for Western Europe and Executive Director for U.S.and Global Research&Development.During Mr.Simmons'tenure, Elanco has significantly increased in size,completed several acquisitions,and become the first independent animal health company to launch ESG commitments and built five new businesses,including a $1 billion pet health business,and a leading aquaculture business.Most recently,he has orchestrated the industry's largest acquisition to date with the completion of Elanco's purchase of Bayer's animal health business.Mr.Simmons has also held a number of leadership positions,including serving as a former board member and Chairman of the Compensation Committee for Chiquita Brands.Mr. Simmons has completed terms as President of the Health for Animals, Chairman of the FFA Foundation Board,and as a board member of Gleaners Food Bank of Indiana.
高管简历
中英对照 | 中文 | 英文- Ramiro M. Cabral
Ramiro M. Cabral自2019年1月起担任Elanco International的执行副总裁。Cabral先生于2018年7月至2018年12月担任Elanco国际和全球客户价值执行副总裁，并于2017年至2018年6月担任Lilly Elanco动物健康部门的副总裁兼首席营销官。他于1998年加入Lilly，并担任Elanco的各种领导职务，包括2013年至2017年在收购和整合Janssen， Lohmann和Novartis动物健康部门期间担任Elanco EMEA的副总裁兼运营主管。他的其他职务包括2011年至2012年担任美国牛肉业务部高级总监，2008年至2010年担任Elanco Canada总经理，2005年至2007年担任全球营销经理。
Ramiro M. Cabral has served as Elanco's Executive Vice President, Elanco International since January 2019. Mr. Cabral served as Executive Vice President, Elanco International and Global Customer Value from July 2018 to December 2018 and as Vice President and Chief Marketing Officer of the Elanco Animal Health division of Lilly from 2017 until June 2018. Mr. Cabral joined Lilly in 1998 and held various leadership positions for Elanco, including Vice President and Head of Operations for Elanco EMEA from 2013 to 2017 during the acquisitions and integrations of Janssen, Lohmann and Novartis Animal Health divisions. Mr. Cabral's other roles include Senior Director, U.S. Beef Business Unit from 2011 to 2012 General Manager of Elanco Canada from 2008 to 2010 and Global Marketing Manager from 2005 to 2007.- Ramiro M. Cabral自2019年1月起担任Elanco International的执行副总裁。Cabral先生于2018年7月至2018年12月担任Elanco国际和全球客户价值执行副总裁，并于2017年至2018年6月担任Lilly Elanco动物健康部门的副总裁兼首席营销官。他于1998年加入Lilly，并担任Elanco的各种领导职务，包括2013年至2017年在收购和整合Janssen， Lohmann和Novartis动物健康部门期间担任Elanco EMEA的副总裁兼运营主管。他的其他职务包括2011年至2012年担任美国牛肉业务部高级总监，2008年至2010年担任Elanco Canada总经理，2005年至2007年担任全球营销经理。
- Ramiro M. Cabral has served as Elanco's Executive Vice President, Elanco International since January 2019. Mr. Cabral served as Executive Vice President, Elanco International and Global Customer Value from July 2018 to December 2018 and as Vice President and Chief Marketing Officer of the Elanco Animal Health division of Lilly from 2017 until June 2018. Mr. Cabral joined Lilly in 1998 and held various leadership positions for Elanco, including Vice President and Head of Operations for Elanco EMEA from 2013 to 2017 during the acquisitions and integrations of Janssen, Lohmann and Novartis Animal Health divisions. Mr. Cabral's other roles include Senior Director, U.S. Beef Business Unit from 2011 to 2012 General Manager of Elanco Canada from 2008 to 2010 and Global Marketing Manager from 2005 to 2007.
- David S. Kinard
David S. Kinard，他一直担任Elanco的执行副总裁，负责人力资源企业事务和行政（2020年8月以来）。他曾担任Elanco的人力资源执行副总裁（从2019年1月到2020年7月）。从2018年7月到2018年12月，担任礼来公司Elanco Animal Health部门的人力资源和全球学习与发展副总裁。金纳德先生2018年5月之前曾在各种礼来公司的领导角色，包括各种礼来公司的人力资源副总裁业务，包括2017年礼来国际生物医药等领域和新兴市场从2015年到2017年，礼来全球糖尿病和员工关系/人力资源操作从2011年到2015年，美国礼来公司2007 - 2011。他职业生涯的前14年在Lilly和AlliedSignal担任组织有效性和人才管理职务。
David S. Kinard has served as Elanco's Executive Vice President, Human Resources Corporate Affairs and Administration since August 2020. Mr. Kinard served as Elanco's Executive Vice President, Human Resources from January 2019 to July 2020 Executive Vice President, Human Resources and Corporate Affairs from July 2018 to December 2018 and as Vice President of Human Resources and Global Learning and Development for the Elanco Animal Health division of Lilly from May 2018 to July 2018. Prior to May 2018 Mr. Kinard served in various leadership roles for Lilly, including Vice President of Human Resources for a variety of Lilly businesses, including Lilly International in 2017 Bio-Medicines and Emerging Markets from 2015 to 2017 Lilly Diabetes and Global Employee Relations/HR Operations from 2011 to 2015 and Lilly USA 2007-2011. Mr. Kinard spent the first 14 years of his career in organizational effectiveness and talent management roles at Lilly and AlliedSignal.- David S. Kinard，他一直担任Elanco的执行副总裁，负责人力资源企业事务和行政（2020年8月以来）。他曾担任Elanco的人力资源执行副总裁（从2019年1月到2020年7月）。从2018年7月到2018年12月，担任礼来公司Elanco Animal Health部门的人力资源和全球学习与发展副总裁。金纳德先生2018年5月之前曾在各种礼来公司的领导角色，包括各种礼来公司的人力资源副总裁业务，包括2017年礼来国际生物医药等领域和新兴市场从2015年到2017年，礼来全球糖尿病和员工关系/人力资源操作从2011年到2015年，美国礼来公司2007 - 2011。他职业生涯的前14年在Lilly和AlliedSignal担任组织有效性和人才管理职务。
- David S. Kinard has served as Elanco's Executive Vice President, Human Resources Corporate Affairs and Administration since August 2020. Mr. Kinard served as Elanco's Executive Vice President, Human Resources from January 2019 to July 2020 Executive Vice President, Human Resources and Corporate Affairs from July 2018 to December 2018 and as Vice President of Human Resources and Global Learning and Development for the Elanco Animal Health division of Lilly from May 2018 to July 2018. Prior to May 2018 Mr. Kinard served in various leadership roles for Lilly, including Vice President of Human Resources for a variety of Lilly businesses, including Lilly International in 2017 Bio-Medicines and Emerging Markets from 2015 to 2017 Lilly Diabetes and Global Employee Relations/HR Operations from 2011 to 2015 and Lilly USA 2007-2011. Mr. Kinard spent the first 14 years of his career in organizational effectiveness and talent management roles at Lilly and AlliedSignal.
- James M. Meer
James M. Meer自2018年9月起担任Elanco的首席会计官。加入Elanco之前，自2017年6月起，他担任Healthx, Inc.（一家医疗保健技术公司）的首席财务官。加入Healthx之前，从2014年到2017年，他担任Appirio（信息技术咨询公司）的财务高级副总裁；从2011年到2014年，他担任Salesforce（之前是ExactTarget（云计算软件公司））的副总裁兼财务总监。2011年之前，他曾在3M（之前是aero Technologies Inc.）、Hill-Rom、Hillenbrand Industries和Ernst & Young LLP担任各种财务、会计和战略职位。
James M. Meer has served as Elanco's Chief Accounting Officer since September 2018. Prior to joining Elanco, Mr. Meer served as the Chief Financial Officer of Healthx, Inc., a healthcare technology company beginning June 2017. Prior to joining Healthx, Mr. Meer served as Senior Vice President of Finance at Appirio, an information technology consulting company, from 2014 to 2017 and as Vice President and Corporate Controller at Salesforce previously ExactTarget, a cloud-based software company, from 2011 to 2014. Prior to 2011 Mr. Meer held various financial, accounting and strategy positions at 3M (previously Aearo Technologies Inc.), Hill-Rom, Hillenbrand Industries and Ernst & Young LLP.- James M. Meer自2018年9月起担任Elanco的首席会计官。加入Elanco之前，自2017年6月起，他担任Healthx, Inc.（一家医疗保健技术公司）的首席财务官。加入Healthx之前，从2014年到2017年，他担任Appirio（信息技术咨询公司）的财务高级副总裁；从2011年到2014年，他担任Salesforce（之前是ExactTarget（云计算软件公司））的副总裁兼财务总监。2011年之前，他曾在3M（之前是aero Technologies Inc.）、Hill-Rom、Hillenbrand Industries和Ernst & Young LLP担任各种财务、会计和战略职位。
- James M. Meer has served as Elanco's Chief Accounting Officer since September 2018. Prior to joining Elanco, Mr. Meer served as the Chief Financial Officer of Healthx, Inc., a healthcare technology company beginning June 2017. Prior to joining Healthx, Mr. Meer served as Senior Vice President of Finance at Appirio, an information technology consulting company, from 2014 to 2017 and as Vice President and Corporate Controller at Salesforce previously ExactTarget, a cloud-based software company, from 2011 to 2014. Prior to 2011 Mr. Meer held various financial, accounting and strategy positions at 3M (previously Aearo Technologies Inc.), Hill-Rom, Hillenbrand Industries and Ernst & Young LLP.
- Robert M. VanHimbergen
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Shiv O'Neill
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Grace McArdle
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Ellen de Brabander
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Timothy J. Bettington
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Rajeev A. Modi
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Jose Manuel Correia de Simas
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Jeffrey N. Simmons
Jeffrey N. Simmonsis Elanco，自2018年7月起担任总裁兼首席执行官。从2008年到2018年9月，Simmons担任礼来公司（Eli Lilly& company’Lilly）的Elanco Animal Health Incorporated总裁和礼来公司的高级副总裁，当时他带领公司从礼来公司分离出来，最终Elanco在纽约证券交易所上市，成为一家专门致力于动物保健的独立上市公司。2008年之前，simmons先生在Elanco担任多个领导职务，包括地区销售经理、国际营销经理、巴西国家总监、西欧地区总监、美国和全球研发执行董事。在他任职期间，Elanco的规模显著扩大，完成了几次收购，成为第一家推出ESG承诺的独立动物保健公司，并建立了五项新业务，包括10亿美元的宠物保健业务和领先的水产养殖业务。最近，他策划了该行业迄今为止最大的收购，完成了Elanco对拜耳动物保健业务的收购。simmons先生还担任过许多领导职务，包括担任Chiquita brands的前董事会成员和薪酬委员会主席。Simmons已经完成了动物健康主席，FFA基金会董事会主席，以及印第安纳州Gleaners Food Bank董事会成员的任期。
Jeffrey N. Simmonsis Elanco's President and Chief Executive Officer,a position he has held since July 2018.Mr.Simmons served as the President of the Elanco Animal Health division of Eli Lilly&Company 'Lilly'and Senior Vice President of Lilly from 2008 until September 2018 when he navigated the company's separation from Lilly, culminating with Elanco's listing on the New York Stock Exchange as an independent public company solely dedicated to animal health.Prior to 2008 Mr.Simmons held various leadership roles for Elanco,including District Sales Manager,International Marketing Manager,Country Director for Brazil,Area Director for Western Europe and Executive Director for U.S.and Global Research&Development.During Mr.Simmons'tenure, Elanco has significantly increased in size,completed several acquisitions,and become the first independent animal health company to launch ESG commitments and built five new businesses,including a $1 billion pet health business,and a leading aquaculture business.Most recently,he has orchestrated the industry's largest acquisition to date with the completion of Elanco's purchase of Bayer's animal health business.Mr.Simmons has also held a number of leadership positions,including serving as a former board member and Chairman of the Compensation Committee for Chiquita Brands.Mr. Simmons has completed terms as President of the Health for Animals, Chairman of the FFA Foundation Board,and as a board member of Gleaners Food Bank of Indiana.- Jeffrey N. Simmonsis Elanco，自2018年7月起担任总裁兼首席执行官。从2008年到2018年9月，Simmons担任礼来公司（Eli Lilly& company’Lilly）的Elanco Animal Health Incorporated总裁和礼来公司的高级副总裁，当时他带领公司从礼来公司分离出来，最终Elanco在纽约证券交易所上市，成为一家专门致力于动物保健的独立上市公司。2008年之前，simmons先生在Elanco担任多个领导职务，包括地区销售经理、国际营销经理、巴西国家总监、西欧地区总监、美国和全球研发执行董事。在他任职期间，Elanco的规模显著扩大，完成了几次收购，成为第一家推出ESG承诺的独立动物保健公司，并建立了五项新业务，包括10亿美元的宠物保健业务和领先的水产养殖业务。最近，他策划了该行业迄今为止最大的收购，完成了Elanco对拜耳动物保健业务的收购。simmons先生还担任过许多领导职务，包括担任Chiquita brands的前董事会成员和薪酬委员会主席。Simmons已经完成了动物健康主席，FFA基金会董事会主席，以及印第安纳州Gleaners Food Bank董事会成员的任期。
- Jeffrey N. Simmonsis Elanco's President and Chief Executive Officer,a position he has held since July 2018.Mr.Simmons served as the President of the Elanco Animal Health division of Eli Lilly&Company 'Lilly'and Senior Vice President of Lilly from 2008 until September 2018 when he navigated the company's separation from Lilly, culminating with Elanco's listing on the New York Stock Exchange as an independent public company solely dedicated to animal health.Prior to 2008 Mr.Simmons held various leadership roles for Elanco,including District Sales Manager,International Marketing Manager,Country Director for Brazil,Area Director for Western Europe and Executive Director for U.S.and Global Research&Development.During Mr.Simmons'tenure, Elanco has significantly increased in size,completed several acquisitions,and become the first independent animal health company to launch ESG commitments and built five new businesses,including a $1 billion pet health business,and a leading aquaculture business.Most recently,he has orchestrated the industry's largest acquisition to date with the completion of Elanco's purchase of Bayer's animal health business.Mr.Simmons has also held a number of leadership positions,including serving as a former board member and Chairman of the Compensation Committee for Chiquita Brands.Mr. Simmons has completed terms as President of the Health for Animals, Chairman of the FFA Foundation Board,and as a board member of Gleaners Food Bank of Indiana.